This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NeoGenomics (NEO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 26.32% and 5.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ITeos Therapeutics, Inc. (ITOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
ITeos Therapeutics, Inc. (ITOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate NeoGenomics (NEO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Aug 10, 2022
by Zacks Equity Research
Companies in The News Are: NEO,H,ARMK,AHCO
NeoGenomics (NEO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 27.27% and 0.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Techne (TECH) Lags Q4 Earnings Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of -0.49% and 0.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Adma Biologics (ADMA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics (NEO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
NeoGenomics (NEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics (NEO) Surges 6.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 13.04% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: NeoGenomics (NEO) Q1 Earnings Expected to Decline
by Zacks Equity Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reata Pharmaceuticals, Inc. (RETA) Stock Jumps 14.5%: Will It Continue to Soar?
by Zacks Equity Research
Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Illumina (ILMN) Debuts TSO Comprehensive Test in Europe
by Zacks Equity Research
Illumina's (ILMN) novel CE-marked IVD kit for comprehensive genomic profiling will enable clinicians to match cancer patients with available therapies.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
NeoGenomics (NEO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of -7.69% and 0.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Bristol Myers Squibb (BMY) Q4 Earnings Meet Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of 0% and 0.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
NeoGenomics (NEO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 0.00% and -1.67%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate NeoGenomics (NEO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
NeoGenomics (NEO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 80.00% and 1.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: NeoGenomics (NEO) Q2 Earnings Expected to Decline
by Zacks Equity Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Advanced Micro Devices, NeoGenomics, Microsoft, Google and Amazon highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Advanced Micro Devices, NeoGenomics, Microsoft, Google and Amazon highlighted as Zacks Bull and Bear of the Day